Annual CFF
$1.50 M
-$1.02 M-40.58%
December 31, 2023
Summary
- As of February 8, 2025, KNSA annual cash flow from financing activities is $1.50 million, with the most recent change of -$1.02 million (-40.58%) on December 31, 2023.
- During the last 3 years, KNSA annual CFF has fallen by -$225.59 million (-99.34%).
- KNSA annual CFF is now -99.57% below its all-time high of $346.74 million, reached on December 31, 2018.
Performance
KNSA Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$6.69 M
+$6.87 M+3857.87%
September 30, 2024
Summary
- As of February 8, 2025, KNSA quarterly cash flow from financing activities is $6.69 million, with the most recent change of +$6.87 million (+3857.87%) on September 30, 2024.
- Over the past year, KNSA quarterly CFF has increased by +$6.14 million (+1111.78%).
- KNSA quarterly CFF is now -96.49% below its all-time high of $190.81 million, reached on March 31, 2018.
Performance
KNSA Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$10.82 M
+$6.14 M+131.08%
September 30, 2024
Summary
- As of February 8, 2025, KNSA TTM cash flow from financing activities is $10.82 million, with the most recent change of +$6.14 million (+131.08%) on September 30, 2024.
- Over the past year, KNSA TTM CFF has increased by +$8.83 million (+443.67%).
- KNSA TTM CFF is now -96.88% below its all-time high of $347.21 million, reached on June 30, 2018.
Performance
KNSA TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
KNSA Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -40.6% | +1111.8% | +443.7% |
| 3 y3 years | -99.3% | +149.6% | +100.9% |
| 5 y5 years | -99.6% | +10000.0% | -87.1% |
KNSA Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -74.6% | at low | at high | +3857.9% | at high | +623.7% |
| 5 y | 5-year | -99.3% | at low | -95.4% | +3857.9% | -95.2% | +623.7% |
| alltime | all time | -99.6% | at low | -96.5% | +977.8% | -96.9% | +623.7% |
Kiniksa Pharmaceuticals Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $6.69 M(-3857.9%) | $10.82 M(+131.1%) |
| Jun 2024 | - | -$178.00 K(-104.9%) | $4.68 M(-6.7%) |
| Mar 2024 | - | $3.61 M(+419.9%) | $5.02 M(+235.7%) |
| Dec 2023 | $1.50 M(-40.6%) | $695.00 K(+25.9%) | $1.50 M(-24.9%) |
| Sep 2023 | - | $552.00 K(+249.4%) | $1.99 M(+10.6%) |
| Jun 2023 | - | $158.00 K(+75.6%) | $1.80 M(-17.6%) |
| Mar 2023 | - | $90.00 K(-92.4%) | $2.18 M(-13.2%) |
| Dec 2022 | $2.52 M(-57.2%) | $1.19 M(+229.6%) | $2.52 M(-0.9%) |
| Sep 2022 | - | $361.00 K(-33.4%) | $2.54 M(-47.7%) |
| Jun 2022 | - | $542.00 K(+28.1%) | $4.86 M(-6.6%) |
| Mar 2022 | - | $423.00 K(-65.1%) | $5.20 M(-11.6%) |
| Dec 2021 | $5.88 M(-97.4%) | $1.21 M(-54.8%) | $5.88 M(+9.3%) |
| Sep 2021 | - | $2.68 M(+202.1%) | $5.38 M(-96.4%) |
| Jun 2021 | - | $887.00 K(-19.8%) | $149.10 M(-34.0%) |
| Mar 2021 | - | $1.11 M(+55.3%) | $225.78 M(-0.6%) |
| Dec 2020 | $227.09 M | $712.00 K(-99.5%) | $227.09 M(+0.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2020 | - | $146.40 M(+88.8%) | $226.75 M(+182.0%) |
| Jun 2020 | - | $77.56 M(+3113.0%) | $80.40 M(+2311.5%) |
| Mar 2020 | - | $2.41 M(+547.2%) | $3.33 M(-96.0%) |
| Dec 2019 | $84.11 M(-75.7%) | $373.00 K(+603.8%) | $84.11 M(+0.1%) |
| Sep 2019 | - | $53.00 K(-89.3%) | $84.03 M(+1.0%) |
| Jun 2019 | - | $494.00 K(-99.4%) | $83.21 M(-65.2%) |
| Mar 2019 | - | $83.19 M(>+9900.0%) | $239.11 M(-31.0%) |
| Dec 2018 | $346.74 M(+769.6%) | $291.00 K(-138.2%) | $346.74 M(+0.1%) |
| Sep 2018 | - | -$762.00 K(-100.5%) | $346.44 M(-0.2%) |
| Jun 2018 | - | $156.40 M(-18.0%) | $347.21 M(+82.0%) |
| Mar 2018 | - | $190.81 M(>+9900.0%) | $190.81 M(+378.5%) |
| Dec 2017 | $39.87 M(-6.2%) | $0.00(0.0%) | $39.87 M(0.0%) |
| Sep 2017 | - | $0.00(0.0%) | $39.87 M(0.0%) |
| Jun 2017 | - | $0.00(-100.0%) | $39.87 M(0.0%) |
| Mar 2017 | - | $39.87 M | $39.87 M |
| Dec 2016 | $42.51 M | - | - |
FAQ
- What is Kiniksa Pharmaceuticals annual cash flow from financing activities?
- What is the all time high annual CFF for Kiniksa Pharmaceuticals?
- What is Kiniksa Pharmaceuticals annual CFF year-on-year change?
- What is Kiniksa Pharmaceuticals quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Kiniksa Pharmaceuticals?
- What is Kiniksa Pharmaceuticals quarterly CFF year-on-year change?
- What is Kiniksa Pharmaceuticals TTM cash flow from financing activities?
- What is the all time high TTM CFF for Kiniksa Pharmaceuticals?
- What is Kiniksa Pharmaceuticals TTM CFF year-on-year change?
What is Kiniksa Pharmaceuticals annual cash flow from financing activities?
The current annual CFF of KNSA is $1.50 M
What is the all time high annual CFF for Kiniksa Pharmaceuticals?
Kiniksa Pharmaceuticals all-time high annual cash flow from financing activities is $346.74 M
What is Kiniksa Pharmaceuticals annual CFF year-on-year change?
Over the past year, KNSA annual cash flow from financing activities has changed by -$1.02 M (-40.58%)
What is Kiniksa Pharmaceuticals quarterly cash flow from financing activities?
The current quarterly CFF of KNSA is $6.69 M
What is the all time high quarterly CFF for Kiniksa Pharmaceuticals?
Kiniksa Pharmaceuticals all-time high quarterly cash flow from financing activities is $190.81 M
What is Kiniksa Pharmaceuticals quarterly CFF year-on-year change?
Over the past year, KNSA quarterly cash flow from financing activities has changed by +$6.14 M (+1111.78%)
What is Kiniksa Pharmaceuticals TTM cash flow from financing activities?
The current TTM CFF of KNSA is $10.82 M
What is the all time high TTM CFF for Kiniksa Pharmaceuticals?
Kiniksa Pharmaceuticals all-time high TTM cash flow from financing activities is $347.21 M
What is Kiniksa Pharmaceuticals TTM CFF year-on-year change?
Over the past year, KNSA TTM cash flow from financing activities has changed by +$8.83 M (+443.67%)